All AbMole products are for research use only, cannot be used for human consumption.
GW501516 (GSK-516, GW1516) is a potent and highly selective PPARβ/δ agonist, with EC50 of 1 nM, with 1000-fold selectivity over hPPARα and hPPARγ. The PPARβ/δ agonist GW501516 inhibited the increase caused by TNF-α in the mRNA levels of the NF-κB target genes interleukin 8 (IL-8), TNF-α and thymic stromal lymphopoietin (TSLP). GW501516 exhibited agonist effects with EC(50) values of 560 and 55 nM against PPARα and PPARδ, respectively, in a luciferase assay. Moreover, GW501516 also exhibited potent ability to induce oleic acid oxidation in a human myotube cell assay with EC(50)=3.7 nM. In contrast, GW501516 treatment decreased TNF-α-induced p65 acetylation. GW501516 increased AMPK phosphorylation and the subsequent p300 phosphorylation, leading to a marked reduction in the association between p65 and this transcriptional co-activator.
 |
Source | Oncotarget (2017). Figure 1. GW501516 |
| Method | migration assay | |
| Cell Lines | MDA-MB-231, MDA-MB-435, and ZR-75-1 cells | |
| Concentrations | 100 nM | |
| Incubation Time | 48 h | |
| Results | Consistent with the results in MDA-MB-231 cells, the migration of other high metastatic human breast cancer cell lines MDA-MB-435 and ZR-75-1 was dose-dependently inhibited in the presence of GW501516 |
| Molecular Weight | 453.5 |
| Formula | C21H18F3NO3S2 |
| CAS Number | 317318-70-0 |
| Solubility (25°C) | DMSO 47 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related PPAR Products |
|---|
| SR1664
SR1664 is an antidiabetic compound that binds to PPARγ and can effectively inhibit CDK5-mediated phosphorylation of PPARγ with IC50 of 80 nM and Ki of 28.67 nM. |
| WY 14643 (Pirinixic Acid)
WY 14643 (Pirinixic Acid) is a potent and selective, peroxisome proliferator-activated receptor-α (PPARα) agonist. |
| Rosiglitazone
Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50=60 nM, Kd=40 nM). Rosiglitazone is an TRPC5 activator (EC50=30 μM) and TRPM3 inhibitor. |
| GSK 3787
GSK3787 is an orally available selective peroxisome proliferator-activated receptor δ (PPARδ) antagonist (pIC50 = 6.6). |
| Rosiglitazone maleate
Rosiglitazone maleate (Avandia) is a potent and selective PPARγ ligand that binds to the PPARγ ligand-binding domain with a Kd value of 43 nM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
